Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Federica MatteucciMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0009-0004-8441-1794
Pegi PavletićMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0000-0002-1467-5792
Alessandro BonifaziDepartment of Pharmacology and Toxicology, Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0002-7306-0114
Rian GarlandDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA.
Hideaki YanoDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA.ORCID 0000-0001-9242-3884
Consuelo AmantiniImmunopathology and Molecular Medicine Unit, School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy.ORCID 0000-0001-8711-9941
Laura ZeppaImmunopathology and Molecular Medicine Unit, School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy.ORCID 0000-0001-6196-9673
Emanuela SabatoDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milano, Italy.ORCID 0000-0002-6965-1894
Giulio VistoliDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milano, Italy.ORCID 0000-0002-3939-5172
Valerio MammoliCenter for Drug Discovery and Development-IDD, Aptuit, an Evotec Company, 37135 Verona, Italy.
Loredana CappellacciMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0000-0001-8155-7211
Fabio Del BelloMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0000-0001-6538-6029
Gianfabio GiorgioniMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0000-0002-9576-6580
Riccardo PetrelliMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0000-0002-4760-1204
Alessia PiergentiliMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0009-0000-7885-0003
Wilma QuagliaMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.
Alessandro PiergentiliMedicinal Chemistry Unit, School of Pharmacy, Chemistry Interdisciplinary Project (ChIP), University of Camerino, 62032 Camerino, Italy.ORCID 0000-0001-6135-6826
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
4-butyl- and 4-benzyl-piperidinesdocking studiesdopamine D4 receptorsglioblastomapotent and selective D4R antagonists
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Novel Potent and Selective Dopamine D4 Receptor Piperidine Antagonists as Potential Alternatives for the Treatment of Glioblastoma. · full record | Socratic